SCYX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	173 075
平均成交量	204 491
市值	66.82M
EPS	$-0.390 ( 2024-03-29 )
下一个收益日期	( $-0.180 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	1.270
ATR14	$0.00800 (0.45%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Sukenick Scott	Sell	15 179	Common Stock
2024-01-26	Angulo Gonzalez David	Buy	290 590	Common Stock
2024-01-26	Angulo Gonzalez David	Buy	431 030	Employee Stock Option (Right to Buy)
2024-01-26	Macleod Ivor	Buy	215 515	Employee Stock Option (Right to Buy)
2024-01-26	Macleod Ivor	Buy	143 675	Common Stock

INSIDER POWER
98.25
Last 93 transactions
Buy: 4 299 100 \| Sell: 614 179

音量相关性

長: 0.03 (neutral)

短: 0.23 (neutral)

Signal:(50.496) Neutral

SCYNEXIS Inc 相关性

10 最正相关
WSBF	0.889
XELA	0.888
ZSAN	0.887
QLGN	0.874
SWVL	0.874
CIVB	0.873
CBAN	0.87
KTTA	0.866
CLBK	0.861
CHMG	0.86

10 最负相关
CROX	-0.88
AVAC	-0.874
FNVT	-0.872
GDNR	-0.871
BTWN	-0.87
XENT	-0.869
MLVF	-0.866
ADAL	-0.864
CNGL	-0.863
HWCC	-0.862

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

SCYNEXIS Inc 相关性 - 货币/商品

0.54
( weak )

0.46
( neutral )

0.00
( neutral )

0.52
( weak )

0.00
( neutral )

-0.46
( neutral )

SCYNEXIS Inc 财务报表

Annual	2023
营收:	$140.14M
毛利润:	$123.71M (88.27 %)
EPS:	$1.400

FY	2023
营收:	$140.14M
毛利润:	$123.71M (88.27 %)
EPS:	$1.400

FY	2022
营收:	$5.09M
毛利润:	$4.46M (87.66 %)
EPS:	$-1.470

FY	2021
营收:	$13.16M
毛利润:	$12.85M (97.63 %)
EPS:	$-1.250

Financial Reports:

No articles found.

SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.